<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04293276</url>
  </required_header>
  <id_info>
    <org_study_id>HR BLTN 014</org_study_id>
    <nct_id>NCT04293276</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer</brief_title>
  <official_title>Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study was to observe the efficacy and safety of treatment with
      pyrotinib and CDK4/6 inhibitor SHR6390 for HER2-positive metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>From the start of treatment to Disease Progress, assessed up to 2 years</time_frame>
    <description>ORR by investigator using RECIST Guideline (Version 1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>from the first drug administration to 30 days from the last dose, assessed up to 2 years</time_frame>
    <description>The number of patients experiencing any adverse events (AE) during the study time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Progression-Free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HER2 positive breast cancer will receive Pyrotinib in combination with SHR6390(at protocol defined dose levels) orally until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib</intervention_name>
    <description>Pyrotinib Tablets</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR6390</intervention_name>
    <description>SHR6390 Tablets</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Local recurrent or metastatic breast cancer suitable for chemotherapy, confirmed
             histologically.

          -  HER2-positive breast cancer(according to 2018 ASCO/CAP HER2 test guideline).

          -  Patients with HER2-positive metastatic breast cancer who had received ≤ 1-line
             treatment in the past;

          -  18-70 years old;

          -  ECOG PS 0-1;

          -  Life expectancy is not less than 12 weeks;

          -  At least one measurable lesion according to RECIST 1.1;

          -  ANC ≥ 2.0×10^9/L, PLT ≥ 100×10^9/L, Hb ≥ 90 g/L; TBIL≤1.5ULN; ALT and AST≤3×ULN(ALT
             and AST≤5×ULN if liver metastasis); BUN and Cr≤1.5×ULN;

          -  LVEF ≥ 50% and QTc≤470 ms.

        Exclusion Criteria:

          -  Patients with symptomatic brain metastasis;

          -  Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors
             affecting drug use and absorption;

          -  patient who received radiotherapy, chemotherapy, surgery (excluding local puncture) or
             molecular targeted therapy within 4 weeks before admission; those who received
             anti-tumor endocrine therapy after screening period;

          -  Participated in other drug clinical trials within 4 weeks before admission;

          -  Tyrosine kinase inhibitors targeting HER2 (Neratinib, Lapatinib, pyrotinib, etc.) have
             been used or are being used in the past;

          -  Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell
             carcinoma or skin squamous cell carcinoma, have been diagnosed in the past five years;

          -  A history of immunodeficiency, including HIV positive, HCV, or other acquired,
             congenital immunodeficiency disorders, or organ transplantation, is known;

          -  Has suffered from any heart disease;

          -  Female patients during pregnancy and lactation, fertile women with positive baseline
             pregnancy tests or women of childbearing age who are unwilling to take effective
             contraceptive measures throughout the trial;

          -  According to the judgement of the researchers, there are concomitant diseases that
             seriously endanger the safety of patients or affect the completion of research
             (including, but not limited to, severe hypertension, severe diabetes, active
             infections, etc.);

          -  Moderate infection occurs within 4 weeks before the first administration (e.g.
             intravenous drip of antibiotics, antifungal or antiviral drugs according to clinical
             criteria), fever(&gt; 38.5 ℃) of unknown origin occurs during the screening period/before
             the first administration;

          -  Researchers believe that patients are not suitable for any other situation in this
             study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Yan, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Yan, Professor</last_name>
    <phone>+86 15713857388</phone>
    <email>ym200678@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Limin Niu</last_name>
    <phone>+86 15838271475</phone>
    <email>1412113302@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Min Yan, Professor</last_name>
      <phone>+86 15713857388</phone>
      <email>ym200678@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>February 29, 2020</last_update_submitted>
  <last_update_submitted_qc>February 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

